MA46972A - Forme polymorphe de sépiaptérine - Google Patents

Forme polymorphe de sépiaptérine

Info

Publication number
MA46972A
MA46972A MA046972A MA46972A MA46972A MA 46972 A MA46972 A MA 46972A MA 046972 A MA046972 A MA 046972A MA 46972 A MA46972 A MA 46972A MA 46972 A MA46972 A MA 46972A
Authority
MA
Morocco
Prior art keywords
sepiapterin
polymorphic form
polymorphic
Prior art date
Application number
MA046972A
Other languages
English (en)
Inventor
Kaito Kishimoto
Taichi Komoda
Daniel E Levy
Takayoshi Matsumoto
Shunichi Murata
Yuichi Shiro
Hiroshi Yoshino
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of MA46972A publication Critical patent/MA46972A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA046972A 2016-11-29 2017-11-28 Forme polymorphe de sépiaptérine MA46972A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29

Publications (1)

Publication Number Publication Date
MA46972A true MA46972A (fr) 2019-10-09

Family

ID=62241955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046972A MA46972A (fr) 2016-11-29 2017-11-28 Forme polymorphe de sépiaptérine

Country Status (8)

Country Link
US (2) US11130760B2 (fr)
EP (1) EP3548487A4 (fr)
JP (1) JP7148532B2 (fr)
CN (1) CN110312721A (fr)
CA (1) CA3043499A1 (fr)
MA (1) MA46972A (fr)
MX (1) MX391156B (fr)
WO (1) WO2018102314A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (fr) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphes de sépiaptérine et leurs sels
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (fr) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions et procedes pour augmenter l'exposition au plasma de tetrahydrobiopterine
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
CA3165636A1 (fr) 2020-01-24 2021-07-29 Neil Smith Methodes de traitement de la maladie de parkinson avec de la sepiapterine
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
AR127191A1 (es) 2021-09-29 2023-12-27 Ptc Therapeutics Inc Composición farmacéutica de sepiapterina
CN117117299B (zh) * 2023-08-14 2024-12-06 国联汽车动力电池研究院有限责任公司 一种无机硫化物固体电解质及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5753656A (en) 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
WO1997007236A1 (fr) 1995-08-18 1997-02-27 Landry Donald W Detection de composes organiques par regulation de reactions catalysees par des anticorps
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
JP2007509909A (ja) 2003-10-31 2007-04-19 アルタナ　ファルマ　アクチエンゲゼルシャフト 呼吸器疾患の治療のためのｂｈ４の使用
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
CA2545968C (fr) 2003-11-17 2010-03-09 Merck Eprova Ag Formes cristallines de dihydrochlorure de (6r)-l-erythro-tetrahydrobiopterine
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (fr) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Méthode de synthèse de dérivés d’hydrazone
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
LT2262790T (lt) 2008-03-10 2017-08-25 Takeda Pharmaceutical Company Limited Benzimidazolo junginio kristalas
WO2010017570A2 (fr) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Forme galénique pharmaceutique contenant de la tétrahydrobioptérine
EP2382216A1 (fr) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Formes de sel d'un composé organique
IN2012DN01453A (fr) 2009-08-20 2015-06-05 Novartis Ag
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (fr) 2011-03-01 2018-05-29 Rubicon Research Private Limited Compositions stables de tetrahydrobiopterine
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) * 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
WO2017218421A1 (fr) 2016-06-13 2017-12-21 Meharry Medical College Modulation de la voie de l'oxyde nitrique synthase pour la santé buccale
WO2018019931A1 (fr) 2016-07-29 2018-02-01 Dipharma S.A. Trousse de composition pharmaceutique comprenant du dichlorhydrate de saproptérine
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
WO2018102315A1 (fr) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphes de sépiaptérine et leurs sels
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (fr) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions et procedes pour augmenter l'exposition au plasma de tetrahydrobiopterine
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Also Published As

Publication number Publication date
JP2020500931A (ja) 2020-01-16
US12325706B2 (en) 2025-06-10
MX2019006207A (es) 2019-11-18
MX391156B (es) 2025-03-21
US20200010469A1 (en) 2020-01-09
US11130760B2 (en) 2021-09-28
EP3548487A4 (fr) 2020-04-29
JP7148532B2 (ja) 2022-10-05
EP3548487A1 (fr) 2019-10-09
CN110312721A (zh) 2019-10-08
CA3043499A1 (fr) 2018-06-07
US20220081443A1 (en) 2022-03-17
WO2018102314A1 (fr) 2018-06-07

Similar Documents

Publication Publication Date Title
EP3548487A4 (fr) Forme polymorphe de sépiaptérine
CY1126998T1 (el) Πολυμορφικες μορφες rad1901-2hcl
PT3687999T (pt) Derivados de rapamicina
IL264143B (en) Processes for preparing olaparib
EP3420388A4 (fr) Égalisation de pupille
EP3337383A4 (fr) Estimation de forme de paupière
EP3509581A4 (fr) Formulations de (r
HUE059158T2 (hu) Eljárás pridopidin elõállítására
PT3457851T (pt) Derivados de sobetiroma
IL267530A (en) Polymorphs
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3668876A4 (fr) Forme polymorphe de tg02
HUE053779T2 (hu) Polimorfok
EP3430073A4 (fr) Composition de polyaryléthercétone
EP3426159A4 (fr) Identification de structures anatomiques
FR3023290B1 (fr) Derives de flavaglines
DK3728208T3 (da) Polymorfer
EP3390422A4 (fr) Formes cristallines de lnt
DK3430004T3 (da) Faststofformer af nilotinibsalte
MA46266A (fr) Formes cristallines
DK3515454T3 (da) Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan
EP3473373A4 (fr) Composition de brasure
EP3529385A4 (fr) Composition de cermet
IL271388B (en) Improved process for preparing imetelstat
EP3395819A4 (fr) Forme cristalline de dérivé aminopyrane substitué